Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients
Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients
Sponsor: Indonesia University
Listed as NCT04457609, this PHASE1 trial focuses on COVID and Pulmonary Infection and remains ongoing. Sponsored by Indonesia University, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Sep 2022 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Indonesia University
For direct contact, visit the study record on ClinicalTrials.gov .